SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (15154)1/8/2005 4:47:24 AM
From: Icebrg  Read Replies (1) | Respond to of 52153
 
>>Looks like plenty of room for Xyotax to improve upon it.>>

Yes, no doubt about that. APPX has chosen an interesting approach to their trial. Instead of - as is normally the case - matching the dosing and hoping for at least an improvement in side-effects, they appear to have tried to match the side effects and show a marginal improvement in treatment effects. They have taken out the CREMAFOR-related side-effects, but not much more.

I am actually surprised there was an approval here. Maybe this is also the reason for the strong CTIC reaction. The share price was up another 4,5 % after hours. I mean, if FDA can approve on data like Abraxane's, Xyotax should be a slam-dunk, if the survival benefits, which seem to be there, are for real.

Erik



To: Biomaven who wrote (15154)1/8/2005 4:12:41 PM
From: Miljenko Zuanic  Read Replies (3) | Respond to of 52153
 
<<Looks like plenty of room for Xyotax to improve upon it.>>

Just to make things clear (one more time): 80-90% of the Xyotrax dose is excreted in urine, intact, so formulation is “too stable”. My view is that drug will not work, or that it will not be significant advantage.

Miljenko


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News